ArticleJournal of the American Heart Association2026
Preclinical Heart Failure: A Dynamic Trajectory of Progression, Regression, and Risk.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding the transition from preclinical heart failure to its symptomatic stages, and its associated biomarker and Doppler echocardiographic changes, is crucial for prevention.
methodsThis was a retrospective cohort study using the STOP-HF (St. Vincent's Screening to Prevent Heart Failure) study. Median follow-up was 4.5 (interquartile range [IQR], 4.4-9.8) years. A total of 1425 participants were classified as stage A (at risk) or stage B (asymptomatic structural/functional abnormalities). Serial assessments included BNP (B-type natriuretic peptide), Doppler echocardiography, and cardiologist review. Progression to stage B required significant interval echocardiographic worsening, and regression required significant improvement. BNP levels and patient events between visits were recorded.
resultsAt visit 1, 67% (n=959) of individuals were stage A and 33% (n=466) stage B. By visit 2, 22% (n=214) of stage A had progressed to stage B (4.4±0.3 per 100 person-years), while 10% of stage B had progressed to stage C (1.6±0.2 per 100 person-years). Stage A progressors had higher baseline BNP (26.4 [IQR, 12.7-53.2] pg/mL) versus nonprogressors (12.6 [IQR, 6.2-25.1] pg/mL;
conclusionsPreclinical heart failure exhibits a bidirectional trajectory, with evidence of regression/stability supporting prevention. Incorporating natriuretic peptide screening enhances risk stratification and effectiveness of preventative screening/intervention services.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.